In today’s recent session, 0.65 million shares of the Day One Biopharmaceuticals Inc (NASDAQ:DAWN) have been traded, and its beta is -1.35. Most recently the company’s share price was $9.31, and it changed around $0.71 or 8.26% from the last close, which brings the market valuation of the company to $943.61M. DAWN at last check was trading at a discount to its 52-week high of $18.07, offering almost -94.09% off that amount. The share price’s 52-week low was $8.02, which indicates that the recent value has risen by an impressive 13.86% since then.
Day One Biopharmaceuticals Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.20. If we narrow it down even further, the data shows that 0 out of 10 analysts rate the stock as a Sell; another 5 rate it as Overweight. Among the rest, 1 recommended DAWN as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Day One Biopharmaceuticals Inc is expected to report earnings per share of -0.42 for the current quarter.
Day One Biopharmaceuticals Inc (NASDAQ:DAWN) trade information
Instantly DAWN has been showing a green trend so far today with a performance of 8.26% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 10.06 on recent trading dayincreased the stock’s daily price by 7.46%. The company’s shares are currently down -26.52% year-to-date, but still down -5.67% over the last five days. On the other hand, Day One Biopharmaceuticals Inc (NASDAQ:DAWN) is -22.87% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $40, which translates to bulls needing to increase their stock price by 76.72% from its current value. Analyst projections state that DAWN is forecast to be at a low of $24 and a high of $45.
Day One Biopharmaceuticals Inc (DAWN) estimates and forecasts
The year-over-year growth rate is expected to be 25.13%, up from the previous year.
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of 31.82M in revenue for the current quarter. 9 analysts expect Day One Biopharmaceuticals Inc to make 38.01M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 363.95%. Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -38.09%.
Day One Biopharmaceuticals Inc (NASDAQ:DAWN)’s Major holders
ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC, with 7.3808% or 6.43 million shares worth $88.61 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF were the top two Mutual Funds as of Sep 30, 2024. The former held 2.46 shares worth $22.93 million, making up 2.43% of all outstanding shares. On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF held roughly 1.82 shares worth around $16.93 million, which represents about 1.79% of the total shares outstanding.
